EMERGENZE IN ONCOLOGIA

Recommendations

Info

TGF-, IGFs,... Tumor cell 1 2 PTHrP/IL-6 TGF-, BMPs, IGFs, FGF, uPA 4 5 Osteoclast Bisphosphonates could interrupt the vicious cycle that favour tumor progression in bone BISPHOSPHONATES 3 Unknown GFs Osteoblast Factors are released by tumor cells that stimulate both osteoclast 1 and osteoblast 2 activity Excessive new bone formation 3 occurs around tumor-cell deposits, resulting in low bone strength and potential vertebral collapse Osteoclastic 4 and osteoblastic 5 activity releases growth factors that stimulate tumor-cell growth, perpetuating the cycle of bone resorption and abnormal bone growth
RELATIVE POTENCIES OF BISPHOSPHONATES Potency relative to pamidronate in vivo (hypercalcemic rat) 1000 800 600 400 200 0 Potencies of bisphosphonates 0,051 Clodronato Clodronate 1,0 7,44 35,9 43,6 847 Pamidronato Pamidronate Alendronato Alendronate Risedronato Risedronate Ibandronato Ibandronate Zoledronic acid Green JR et al: J Bone Miner Res 1994; 9:745-51
Page 1 and 2: EMERGENZE IN ONCOLOGIA
Page 3 and 4: Anamnesi Oncologica: CASO CLINICO -
Page 5 and 6: CASO CLINICO - In data 24/01/2011 i
Page 7 and 8: CASO CLINICO - All’ingresso in re
Page 9 and 10: Le manifestazioni cliniche sono cor
Page 11 and 12: - è la più comune emergenza metab
Page 13 and 14: CAUSE DI IPERCALCEMIA NON NEOPLASTI
Page 15 and 16: Renal cancer cells PTHrP Ca ++ Incr
Page 17 and 18: FISIOPATOLOGIA DELL’IPERCALCEMIA
Page 19 and 20: METASTASI OSSEE: DIMENSIONI DEL PRO
Page 21 and 22: IPERCALCEMIA: MANIFESTAZIONI CLINIC
Page 23 and 24: IPERCALCEMIA: MANIFESTAZIONI CLINIC
Page 25: TRATTAMENTO DELL’IPERCALCEMIA FOR
Page 29 and 30: EFFETTI COLLATERALI DEI BISFOSFONAT
Page 31 and 32: TRATTAMENTO DELL’IPERCALCEMIA FOR
Page 33 and 34: CASO CLINICO Dopo le prime 24 ore d
Page 35 and 36: QUALE ITER TERAPEUTICO ASSISTENZIAL
Page 37 and 38: R.L. Uomo di 71 anni Anamnesi Famil
Page 39 and 40: CASO CLINICO Nell’ultima settiman
Page 41 and 42: CASO CLINICO Esame istologico: quad
Page 43 and 44: SINDROME DA INAPPROPRIATA SECREZION
Page 45 and 46: SIADH
Page 47 and 48: SIADH ADH (o sostanza polipeptidica
Page 49 and 50: SIADH SINDROMI PARANEOPLASTICHE END
Page 51 and 52: SIADH IPONATRIEMIA SEVERA ACUTA E
Page 53 and 54: SIADH TERAPIA 1) IDENTIFICARE e TR
Page 55 and 56: T.M. Donna di 55 anni CASO CLINICO
Page 57 and 58: CASO CLINICO Durante l’ultimo cic
Page 59 and 60: SINDROME DA COMPRESSIONE MIDOLLARE
Page 61 and 62: PATHOPHYSIOLOGY SPINAL CORD COMPRES
Page 63 and 64: SPINAL CORD COMPRESSION PATHOPHYSI
Page 65 and 66: SPINAL CORD COMPRESSION CLINICAL P
Page 67 and 68: DIAGNOSIS SPINAL CORD COMPRESSION
Page 69 and 70: SPINAL CORD COMPRESSION PATIENT ME
Page 71 and 72: SPINAL CORD COMPRESSION Variables a
Page 73 and 74: SPINAL CORD COMPRESSION PATIENT ME
Page 75 and 76: QUALE ITER TERAPEUTICO ASSISTENZIAL
Page 77 and 78:
SINDROME DELLA VENA CAVA SUPERIORE
Page 79 and 80:
ETIOLOGIA SINDROME DELLA VCS NEOPLA
Page 81 and 82:
DIAGNOSI SINDROME DELLA VCS • Rx
show all

EMERGENZE IN ONCOLOGIA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?